• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    J&J’s Single-Dose COVID-19 Vax Issued EUA

    Icon to Acquire PRA Health Sciences

    Phlow Corp. and USP Form Alliance

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    BMS Expands Cell Therapy Manufacturing Capabilities

    Novo Nordisk Invests $80M in Tablet Production

    Arcline Investment Acquires ChargePoint Technology

    Solid Dose Market Trends

    CatSci Opens New Site in UK
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reshaping the Pharmaceutical Supply Chain

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Icon to Acquire PRA Health Sciences

    BMS Expands Cell Therapy Manufacturing Capabilities

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Flow Sciences

    Emergent BioSolutions

    Cytovance Biologics

    Reed-Lane

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Syngene

    Adare Pharma Solutions

    PCI Pharma Services

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Back Page

    Biopharma Nomenclature

    Citizen petition requests biopharmaceutical names and information be disclosed by FDA

    Related CONTENT
    • CDMO Recro Strengthens Leadership Team
    • Samsung Biologics Names John Rim as President and CEO
    • Bye-Bye China?
    • Mogene
    • Frontida BioPharm Names Steven Roese as Vice President, Quality
    Ronald A. Rader, Biotechnology Information Institute09.05.13
    The Biotechnology Information Institute (of which I am president) has filed a Citizen Petition requesting that FDA assign both unique and biosimilar/(bio)generic-type (or class) names (and/or other identifiers) to approved biologic products and their active agents, along with disclosures of sufficient public information to enable an adequate understanding of product identity (what the products/agents are, which is largely dependent on their composition, bioprocessing and quality-related (CMC) aspects). The petition also requests information regarding nomenclature and product identity (CMC) aspects be disclosed prior to approval and discussed as part public advisory committee meetings. Further information on the petition is available at www.biopharmacopeia.com.

    Biopharma products are each unique and differentiated on the basis of their composition, bioprocessing and quality-related (CMC) aspects, with any significant CMC changes defining a new product and thus requiring a new approval, either supplemental or full BLA. This petition requests FDA assign names (and/or other identifiers) to products and agents upon impending approval. The petition also requests: unique names/identifiers and related information disclosures concerning supplemental BLA changes in products/agents (tracking of product drift); and that any nomenclature for names/identifiers be coherent, science/product/entity-based and unencumbered by legacy regulatory requirements.

    Despite biopharmaceuticals being the most complex of all consumer products, these products lack both unique and generic-type descriptive or otherwise useful authoritative non-proprietary (publically-usable) names! Currently there are no non-proprietary names (no nomenclature systems) for approved biologics that reflect the nature of the products (and active agents), what they are, with current non-proprietary names highly constrained by regulatory requirements. The official (established/compendial/USAN) non-proprietary names assigned by FDA, widely used for marketing and prescriptions, are insufficiently descriptive (short, for writing prescriptions), are not linked to any product/agent descriptions (are totally undefined), and do not change as the products/agents change (track product drift). Further, these names are fully ambiguous, with the same names, e.g., rituximab, used as both the name for the product and the active agent, with those encountering the names having to guess by context whether a name is referring to a product or agent. This may work well enough for generic small molecule drugs, but not for biopharmaceuticals — which are defined by their unique bioprocessing — particularly in the context of hundreds of biosimilars set to enter the U.S. market.

    The petition has nothing to do with official names for these products. These have been the subject of years of yet-to-be-resolved controversies over what type official names FDA should assign to biosimilars, e.g., unique or (bio)generic names. Otherwise, biosimilar/(bio)generic or class names for biologic products and active agents simply do not exist yet.

    It is very common for FDA review information related to product composition, bioprocessing and CMC aspects to have been 100% redacted (censored), as illustrated with multiple products in an appendix to the petition. In fact, the few descriptive sentences included in product inserts are often more informative than the cumulative product approval-related documentation available from FDA! The petition seeks more substantive and useful product/agent-related disclosures in review-related public documentations. Currently, lacking both useable names/ identifiers and the most basic authoritative descriptive information, biopharmaceuticals risk being tagged as “Frankenpharma-ceuticals,” as has happened with GMO food products.

    The petition also requests that FDA’s proposed names and product-defining information, including CMC aspects, be discussed at public advisory committee meetings. Neither the public documents disclosed prior to these meetings nor the meetings themselves now include discussion of CMC-related aspects, which are much more a determinant and critical for an understanding of product safety than the minutiae of clinical studies, which now dominate these meetings.

    No matter what names/identifiers FDA assigns to biologics, expert input and representation of diverse interests (uses/user communities) should be an integral part of developing names — the candidates for selection by FDA and other names for other uses/user communities. Regrettably, the U.S. biopharma industry lacks its own dedicated trade association that normally would be involved hands-on with such issues. The petitioner has proposed the U.S. Biopharmacopeia™ Registry of Biopharmaceutical Products project to propose candidate unique and non-unique names for biopharmaceutical products/ agents suitable for selective adoption by diverse user communities, including regulatory agencies, formularies, reference sources, public use, etc.; and post a public website providing this information. The Biopharmacopeia project might function similar to the CTFA/PCPA (cosmetics trade association) Dictionary project, which for nearly 40 years has involved an industry-based committee proposing cosmetic ingredient names to FDA, with these almost always adopted for official product labeling.


    Ronald. A. Rader is president, Biotechnology Information Institute, and the author/publisher of BIOPHARMA: Biopharma-ceutical Products in the U.S. and European Markets (biopharma.com). For further information or to lend your support to the petition, contact Mr. Rader at biotech@biopharma.com.
    Related Searches
    • Biopharma
    • Biosimilars
    • CMC
    Suggested For You
    CDMO Recro Strengthens Leadership Team CDMO Recro Strengthens Leadership Team
    Samsung Biologics Names John Rim as President and CEO Samsung Biologics Names John Rim as President and CEO
    Bye-Bye China? Bye-Bye China?
    Mogene Mogene
    Frontida BioPharm Names Steven Roese as Vice President, Quality Frontida BioPharm Names Steven Roese as Vice President, Quality
    Avomeen Names SVP of Lab Operations Avomeen Names SVP of Lab Operations
    Metrics Contract Services Expands Business Development Team Metrics Contract Services Expands Business Development Team
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PCI Biotech, RXi Pharma Extend Research Collaboration PCI Biotech, RXi Pharma Extend Research Collaboration
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    Sartorius Partners with Nova Biomedical Sartorius Partners with Nova Biomedical
    Kemwell Provides Services for U.S. Trial Kemwell Provides Services for U.S. Trial
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    DelMar Collaborates with PRA Health Sciences DelMar Collaborates with PRA Health Sciences

    Related Back Page

    • Biologics, Proteins, Vaccines | Biosimilars | R&D
      The Global Biotech Boom

      The Global Biotech Boom

      How an industry grew to lead health care innovation and how CROs are adapting to meet their needs.
      Davide Garrisi, PPD Biotech 09.09.20

    • Biologics, Proteins, Vaccines | Biosimilars
      Biotech Booms in the Yangtze River Valley

      Biotech Booms in the Yangtze River Valley

      A look at forces shaping the course of biotech growth in China
      Daniel Burch, M.D., Global Medical Officer, PPD Biotech 05.07.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Biogenerics Progress

      Biogenerics Progress

      Generic makers target big forays into major markets
      S. Harachand, Contributing Editor 06.12.18


    • Analytical Services | Biosimilars

      How to Build Better Proteins

      Advancing the next generation of biologics
      Aileen Ruff, Catalent 03.09.16

    • Biosimilars | Validation

      Biosimilars on the Horizon

      The emerging biosimilar market is ripe with opportunities for CROs and CMOs to imprint their brand
      Cliff Echols, Bluebox Research 10.07.15

    Trending
    • Bormioli Opens New Glass Research Center
    • Arcline Investment Acquires ChargePoint Technology
    • Spark Therapeutics Appoints CTO
    • The Future Of Vaccines And Biologics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • J&J’s Single-Dose COVID-19 Vax Issued EUA
    • Icon to Acquire PRA Health Sciences
    • Phlow Corp. and USP Form Alliance
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Novo Nordisk Invests $80M in Tablet Production
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Martin Bauer Group Acquires Majority Stake in Beverage Company Power Brands
    Gencor Announces Positive Results in VeriSperse Bioavailability Study
    PanTheryx Inc. Acquires TruBiotics Brand from Bayer HealthCare LLC
    Coatings World

    Latest Breaking News From Coatings World

    Mule-Hide Products Co. Promotes Steven Litaker to Territory Manager
    Terra Firma, Wanhua Announce New Distribution Partnership
    Gelest CEO Elected to National Academy of Engineering
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Axonics Buys Contura to Expand to Stress Urinary Incontinence
    Nurx Appoints Chief Medical Officer
    Median Technologies, UC San Diego to Partner on AI-Based Medical Imaging Technology
    Contract Pharma

    Latest Breaking News From Contract Pharma

    J&J’s Single-Dose COVID-19 Vax Issued EUA
    Icon to Acquire PRA Health Sciences
    Phlow Corp. and USP Form Alliance
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Universal Engraving Announces New President
    Raw Sugar Living Expands to Target with New Collection
    Supporting Female Beauty Brand Founders on International Women's Day
    Happi

    Latest Breaking News From Happi

    ACI and CBC Launch Webpage About ‘Quats’
    L’Occitane Launches Hand Cream Inspired by Women
    Kiehl’s Partners with Gyrl Wonder
    Ink World

    Latest Breaking News From Ink World

    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI analyzes pandemic's effect on label industry in new report
    UEI names Ross Hutchison president
    Schreiner MediPharm and AARDEX partner for clinical trials
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    U.S. Nonwovens Rebrands as Radienz Living
    What You’re Reading on Nonwovens-Industry.com
    Texas Medical Technology Partners with My Protect Kit
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Pandemic Pain: NuVasive's 2020 Sales Fall 10 Percent
    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login